Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04313881 · ClinicalTrials.gov registry record · Phase 3
Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)
A Phase 3 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 3
- Development phase
- 539
- Enrollment target
NCT04313881 is a Phase 3 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 539 participants.
The verdict
NCT04313881, a Phase 3 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 539 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the efficacy of magrolimab in combination with azacitidine compared to that of azacitidine plus placebo in previously untreated participants with intermediate/high/very high risk myelodysplastic syndrome (MDS) by Revised International Prognostic Scoring System (IPSS-R) as measured by complete remission (CR) and overall survival (OS).
Interventions
- DRUG Placebo
- DRUG Azacitidine
- DRUG Magrolimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 539 participants |
| Start Date | 2020-09-09 |
| Est. Completion | 2023-09-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04313881
The ClinicalTrials.gov registry entry for NCT04313881 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 539 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04313881 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04313881 about?
NCT04313881 is a clinical study titled "Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)". The primary objective of this study is to evaluate the efficacy of magrolimab in combination with azacitidine compared to that of azacitidine plus placebo in previously untreated participants with intermediate/high/very high risk myelodysplastic syndrome (MDS) by Revised International Prognostic Sco...
What is the current status of trial NCT04313881?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 539 participants. The study started on 2020-09-09. Estimated completion is 2023-09-13.
What interventions are being tested in trial NCT04313881?
The interventions under investigation include: Placebo (DRUG), Azacitidine (DRUG), Magrolimab (DRUG).
Who is sponsoring clinical trial NCT04313881?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.